PVCTOTCPharmaceutical PreparationsFiscal year ends December 31
PROVECTUS BIOPHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.05+0.00 (+0.39%)
Close on Oct 19, 2026
- Market cap
- $20.55M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.0264 (−35.06%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
PROVECTUS BIOPHARMACEUTICALS, INC. saw revenue fall 45.5% to $336.11K over fiscal 2025.
Revenue
$336.11K
-45.5% vs. a year earlier
Operating income
-$4.58M
TTM Q2 2026
EPS, diluted
$0.00
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $20.55M
- P/E ratio
- –
- Price to sales
- 61.15
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $336.11K
- Net income
- -$4.75M
- EPS, diluted
- $0.00
- Book value per share
- -$0.01
- Diluted shares
- 420M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
–
Gross profit
–
Operating income
-$4.58M
Net income
-$4.75M
EPS, diluted
$0.00
Free cash flow
–
Reported periodTrailing twelve months